Thiazoles as modulators of RORγt

Patent metadata

Field	Value
Publication number	US-10080744-B2
Application number	US-201715812528-A
Country	US
Kind code	B2
Filing date	Nov 14, 2017
Priority date	Oct 30, 2014
Publication date	Sep 25, 2018
Grant date	Sep 25, 2018

Abstract

The present invention comprises compounds of Formula I

wherein:

R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , R 8 , and {circle around (A)} are defined in the specification.

The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

First claim

We claim:

1. A method for treating or ameliorating a RORγt mediated inflammatory syndrome, disorder or disease selected from the group consisting of: inflammatory bowel diseases, rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disorder, psoriatic arthritis, ankylosing spondylitis, neutrophilic asthma, steroid resistant asthma, multiple sclerosis, and systemic lupus erythematosus comprising administering to a subject in need thereof an effective amount of a compound of Formula I:

wherein:

 Z is N, or CH;
R 1 is H, Cl, OCF 3 , C (1-3) alkyl, —CN, F, OC (1-3) alkyl, OCHF 2 , Br, I, or cyclopropyl; wherein said C (1-3) alkyl is optionally substituted with up to five fluorine atoms;
R 2 is H, F, Cl, —CN, OCH 3 , OCHF 2 , OCF 3 , cyclopropyl, or C (1-4) alkyl; wherein said C (1-4) alkyl is optionally substituted with up to five fluorine atoms, and said cyclopropyl is optionally substituted with OH, CH 3 , CF 3 , —CN, and up to five fluorine atoms; or R 1 and R 2 may be taken together with their attached ring A to form a fused ring system selected from the group consisting of naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, and quinolinyl, wherein said naphthalenyl, isoquinolinyl, tetrahydronaphthalenyl, and quinolinyl are optionally substituted with F, CHF 2 , CH 2 F, CF 3 , or CH 3 ; provided that R 2 may not be H if R 1 is H;
R 3 is oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, tetrazolyl, 1,2,4-oxadiazol-5(4H)-on-3-yl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, or pyrrolyl; wherein said oxadiazolyl, thiazolyl, thiadiazolyl, isoxadiazolyl, isoxazolyl, phenyl, oxazolyl, triazolyl, pyridyl, pyrimidyl, pyridazyl, pyrazyl, imidazolyl, or pyrrolyl is optionally substituted with R 6 ;
R 6 is

 C (1-4) alkyl, C(O)NH 2 , or —CN; wherein said C (1-4) alkyl is optionally substituted with up to six fluorine atoms, CO 2 H, OH, or —CN;

R 4 is C (3-6) cycloalkyl, isopropyl, C(CH 3 ) 2 OCH 3 , OC (1-4) alkyl, fluorophenyl, difluorophenyl, pyridyl, CH 2 SO 2 CH 3 , or NA 1 A 2 , wherein said C (3-6) cycloalkyl is optionally substituted with OCH 3 , two fluoro groups or two methyl groups;
A 1 is H, or C (1-3) alkyl; wherein said C (1-3) alkyl is optionally substituted with up to five fluorine atoms, Cl, —CN, OCH 3 , OCHF 2 , or OCF 3 ;
A 2 is C (1-4) alkyl, C (0-2) alkyl-C (3-6) cycloalkyl, CH 2 —C 6 H 4 —C(O)NH 2 , —C 6 H 4 —F, or CH 2 —CCH; wherein said C (1-4) alkyl, and said C (0-2) alkyl-C (3-6) cycloalkyl are optionally substituted with up to three fluorine atoms, Cl, —CN, OCH 3 , OCHF 2 , or OCF 3 ;
or A 1 and A 2 may be taken together with their attached nitrogen to form a ring selected from the group consisting of:

thiomorpholinyl, piperidinyl, pyrrolidinyl, piperazinyl, and morpholinyl; wherein said piperidinyl, pyrrolidinyl, piperazinyl, and morpholinyl are optionally substituted with CF 3 , CH 2 F, CH 2 CH 2 F, C (1-2) alkyl, —CN, OH, CH 2 OH, F, Cl, OCH 3 , OCHF 2 , or OCF 3 , and up to three additional substituents selected from the group consisting of CH 3 , and F;

R 5 is SO 2 NA 3 A 4 , C (1-6) alkyl,

 wherein said C (1-6) alkyl is optionally substituted with OH, Cl, —CN, OCH 3 , OCHF 2 , OCF 3 , or NA 3 A 4 ; and up to six fluorine atoms;
A 3 is H, or C (1-4) alkyl; wherein said C (1-4) alkyl is optionally substituted with OH, Cl, —CN, OCH 3 , OCHF 2 , or OCF 3 ; and up to six fluorine atoms;
A 4 is C (1-6) alkyl, C (3-6) cycloalkyl, oxetanyl, or tetrahydrofuranyl; wherein said C (1-6) alkyl is optionally substituted with cyclopropyl, morpholinyl, OH, OCH 3 , or C(O)NH 2 , and additionally substituted with up to three fluorine atoms; and wherein said C (3-6) cycloalkyl, oxetanyl, and tetrahydrofuranyl are optionally substituted with CF 3 , CH 3 , —CN, or C(O)NH 2 ;
or A 3 and A 4 can be taken together with their attached nitrogen to form a ring selected from the group consisting of azetidinyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl wherein said azetidinyl, piperidinyl, morpholinyl, and piperazinyl are optionally substituted with up to four groups selected from the group consisting of CF 3 , OH, and CH 3 ; and further optionally substituted with up to six fluorine atoms;

R 7 is H, F, OH, or OCH 3 ;
R 8 is H;
and pharmaceutically acceptable salts thereof.

2. The method of claim 1 , wherein the disease is psoriasis.

3. The method of claim 1 , wherein the disease is rheumatoid arthritis.

4. The method of claim 1 , wherein the inflammatory bowel disease is ulcerative colitis.

5. The method of claim 1 , wherein the inflammatory bowel disease is Crohn's disease.

6. The method of claim 1 , wherein the disease is multiple sclerosis.

7. The method of claim 1 , wherein the disease is neutrophilic asthma.

8. The method of claim 1 , wherein the disease is steroid resistant asthma.

9. The method of claim 1 , wherein the disease is psoriatic arthritis.

10. The method of claim 1 , wherein the disease is ankylosing spondylitis.

11. The method of claim 1 , wherein the disease is systemic lupus erythematosus.

12. The method of claim 1 , wherein the disease is chronic obstructive pulmonary disorder.

13. A method of treating or ameliorating a syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject an effective amount of a compound of claim 1 or composition or medicament thereof in a combination therapy with one or more anti-inflammatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is selected from the group consisting of: rheumatoid arthritis, and psoriasis.

14. The method of claim 1 wherein the compound is selected from the group consisting of:

Assignees

• Janssen Pharmaceutica Nv

Inventors

• Goldberg Steven
• Steeneck Christoph
• Gege Christian
• Kinzel Olaf
• Kleymann Gerald
• Hoffmann Thomas
• Fourie Anne M
• Xue Xiaohua

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title